Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

Trial Details

NCT ID

NCT05281809

Phase

PHASE2

Sponsor

John Lister

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)

Locations (sample)

• Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

• Subjects with CD19+ B-cell lymphoma or B-Cell Acute Lymphoblastic Leukemia (B-ALL) with no currently available curative treatment option (such as a…
• Peripheral blood CD3 count \> 200/µL by flow cytometry. Please note that this test might need to be repeated multiple times as standard practice to…
• Subjects will have a diagnosis of Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), CLL, Marginal Zone L…
• Subjects with pathological and clinical evidence of transformed indolent lymphoma (FL, CLL, MZL or LPL) are eligible for participation on this tria…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.